Maryam Khawari, MD
Rheumatology · Katy, TXNPI 1346381365
Payments from drug & device makers
Across 182 payments — averaging $4976.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$689K
- AbbVie$156K
- Argenx US, Inc.$22K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$20K
- Eli Lilly$18K
- ANI Pharmaceuticals, Inc.$224
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,270100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 40 | $688,639 |
| AbbVie | 39 | $155,630 |
| Argenx US, Inc. | 23 | $22,176 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $20,150 |
| Eli Lilly | 3 | $17,500 |
| ANI Pharmaceuticals, Inc. | 8 | $224 |
| Bayer | 9 | $188 |
| Novartis | 6 | $176 |
| Mallinckrodt Hospital Products Inc. | 6 | $158 |
| AstraZeneca(2 entities) | 7 | $157 |
| Johnson & Johnson(2 entities) | 9 | $134 |
| Lilly USA, LLC | 5 | $101 |
| Calliditas Therapeutics US Inc. | 4 | $94 |
| Fresenius Kabi USA, LLC | 3 | $71 |
| Radius Health, Inc. | 3 | $66 |
| UCB, Inc. | 3 | $65 |
| GSK | 3 | $55 |
| Sanofi | 2 | $46 |
| Tersera Therapeutics LLC | 1 | $31 |
| Aurinia Pharma U.S., Inc. | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Biogen | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| GE HealthCare | 1 | $11 |
How this compares
$905,806 in reported general payments places this provider in the 90th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 36 | $260,567 |
| Hydroxychloroquine Sulfate | 227 | $7,557 |
| Mycophenolate Mofetil | 38 | $3,585 |
| Leflunomide | 74 | $3,377 |
| Celecoxib | 73 | $3,018 |
| Colchicine | 22 | $1,844 |
| Prednisone | 284 | $1,277 |
| MethotrexateMethotrexate Sodium | 113 | $1,261 |
| Azathioprine | 29 | $1,102 |
| Duloxetine Hcl | 40 | $571 |
| Febuxostat | 19 | $551 |
| Dapsone | 11 | $467 |
| Diclofenac Sodium | 11 | $294 |
| Gabapentin | 44 | $256 |
| Allopurinol | 39 | $253 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Katy
- Kiran FarheenKaty$703K
- Tara RizviKaty$644K
- Paul PickrellAustin$40.9M
- Atul SinghalMesquite$13.9M
- Shaikh AliTomball$9.8M
- Jitendra VasandaniLubbock$6.4M
- Dhiman BasuColleyville$6.2M
- Tamar BrionezThe Woodlands$5.2M
- Philip WallerHouston$4.9M
- John CushDallas$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.